Literature DB >> 25350962

Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Angiola Rocino1, Antonio Coppola2, Massimo Franchini3, Giancarlo Castaman4, Cristina Santoro5, Ezio Zanon6, Elena Santagostino7, Massimo Morfini8.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25350962      PMCID： PMC4212040          DOI： 10.2450/2014.0223-14

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  183 in total

Review 1.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.

Authors:  E Tabor
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

2.  Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.

Authors:  D A Roth; C M Kessler; K J Pasi; B Rup; S G Courter; K L Tubridy
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

3.  How to start prophylaxis.

Authors:  P Petrini
Journal:  Haemophilia       Date:  2003-05       Impact factor: 4.287

4.  Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events.

Authors:  H J Ehrlich; M J Henzl; E D Gomperts
Journal:  Haemophilia       Date:  2002-03       Impact factor: 4.287

5.  Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency.

Authors:  Ophira Salomon; Ariella Zivelin; Tami Livnat; Rima Dardik; Ron Loewenthal; Ophelia Avishai; David M Steinberg; Michael H Rosove; Niamh O'Connell; Christine A Lee; Uri Seligsohn
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

6.  Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome.

Authors:  K Fischer; J G Van Der Bom; R Prejs; E P Mauser-Bunschoten; G Roosendaal; D E Grobbee; H M Van Den Berg
Journal:  Haemophilia       Date:  2001-11       Impact factor: 4.287

7.  Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans.

Authors:  P Brown; L Cervenáková; L M McShane; P Barber; R Rubenstein; W N Drohan
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

8.  Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-01-03       Impact factor: 17.586

9.  The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

Authors:  J M Lusher; C A Lee; C M Kessler; C L Bedrosian
Journal:  Haemophilia       Date:  2003-01       Impact factor: 4.287

Review 10.  The epidemiology of inhibitors in haemophilia A: a systematic review.

Authors:  J Wight; S Paisley
Journal:  Haemophilia       Date:  2003-07       Impact factor: 4.287
View more
  21 in total

1.  Errata corrige.

Authors: 
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

2.  Italian consumption of plasma-derived factor VIII after the SIPPET study.

Authors:  Giuseppe Traversa; Francesco Trotta
Journal:  Blood Transfus       Date:  2017-05       Impact factor: 3.443

3.  The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A.

Authors:  Antonio Coppola; Elena Santagostino; Hamisa J Hassan; Angelo C Molinari; Rita C Santoro; Annarita Tagliaferri; Massimo Morfini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2017-03-02       Impact factor: 3.443

4.  Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

Authors:  Annarita Tagliaferri; Annalisa Matichecchia; Gianna F Rivolta; Federica Riccardi; Gabriele Quintavalle; Anna Benegiamo; Rossana Rossi; Antonio Coppola
Journal:  Blood Transfus       Date:  2019-11-04       Impact factor: 3.443

5.  Clinical relevance of isolated prolongation of the activated partial thromboplastin time in a cohort of adults undergoing surgical procedures.

Authors:  Giuseppe Tagariello; Paolo Radossi; Roberta Salviato; Milena Zardo; Lucia De Valentin; Marco Basso; Giancarlo Castaman
Journal:  Blood Transfus       Date:  2016-07-22       Impact factor: 3.443

6.  The increased demand for plasma-derived factor VIII in Italy.

Authors:  Romano Arcieri; Gabriele Calizzani; Fabio Candura; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2016-07-28       Impact factor: 3.443

7.  New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey.

Authors:  Francesca Abbonizio; Hamisa J Hassan; Roberta Riccioni; Elena Santagostino; Romano Arcieri; Adele Giampaolo
Journal:  Blood Transfus       Date:  2019-02-13       Impact factor: 3.443

Review 8.  Management of Hemophilia in Older Patients.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

Review 9.  Rare congenital bleeding disorders.

Authors:  Massimo Franchini; Giuseppe Marano; Simonetta Pupella; Stefania Vaglio; Francesca Masiello; Eva Veropalumbo; Vanessa Piccinini; Ilaria Pati; Liviana Catalano; Giancarlo Maria Liumbruno
Journal:  Ann Transl Med       Date:  2018-09

10.  The risk of venipuncture in newborn with severe hemophilia: Case report of a large elbow hemorrhage and literature review of compartment syndrome.

Authors:  Giuseppe Lassandro; Anna Amoruso; Valentina Palladino; Viviana Valeria Palmieri; Paola Giordano
Journal:  Hematol Rep       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.